Objective-Haemodialysis is associated with the deposition of 2 microglobulin in musculoskeletal structures, leading to the syndrome of dialysis related amyloidosis and impairment of hand function. This study aimed at assessing hand function using the Sollerman test in a cross section of patients undergoing haemodialysis. 
Haemodialysis in chronic renal failure does not adequately restore all avenues of normal renal function. Clinically relevant is the retention and preferential deposition in musculoskeletal structures of 2 microglobulin, an 11.8 kDa polypeptide. 1 The clinical manifestations of this deposition are broadly known as dialysis related amyloidosis, and include a destructive arthropathy, 2 erosive spondyloarthropathy, 3 and bone cysts. 4 Carpal tunnel syndrome is common and, together with flexor tendon contractures and trigger finger, is known to aVect hand function adversely, 5 which may, in turn, impede activities of daily living.
Measurement of hand function in patients with dialysis related amyloidosis is not well described. A single study of hand function used a method devised for medicolegal purposes and not primarily to reflect hand grips as needed in activities of daily living. 5 The Sollerman test assesses unilateral and bilateral hand grip function in activities of daily living. 6 This test has been validated against other tests of hand function (Jebsen test of hand function), 7 8 and inter-rater coeYcient of reliability is high, r=0.98 (Doehr SL, unpublished data).
We aimed at undertaking a cross sectional analysis of hand grip function using the Sollerman test in patients receiving haemodialysis, and correlating this test with other measures used to evaluate the functional impact of arthropathy.
Patients and methods

PATIENTS
Patients receiving hospital or community based haemodialysis for more than one month, through the Queen Elizabeth Hospital, were invited to participate after obtaining their informed consent. Inflammatory arthritis and peripheral neuropathy were exclusion criteria.
GENERAL
Demographic data were obtained, along with details of haemodialysis (frequency, duration, dialyser type, and membrane), prior renal transplantation, parathyroidectomy, hand dominance, carpal tunnel syndrome, and symptoms of peripheral/axial arthritis. The visual analogue scale for pain, VAS-P (place a vertical mark on the line below to represent the pain you experienced in your hands over the past 24 hours) and function, VAS-F (consider the way your hands are aVected and place a vertical mark on the line below to represent how you are doing), and the Health Assessment Questionnaire (HAQ) scores were determined by standard techniques. All subjects underwent the JAMAR test (JA Preston Corp, Ontario, Canada) for hand grip strength and the Sollerman test (Exelfort Pty Ltd, Cottesloe) for the dominant (D) and non-dominant (ND) hands with a single occupational therapist. The JAMAR hand dynamometer measures grip strength by isometric muscle contraction, and is performed in the sitting position, with the shoulder adducted, elbow flexed to ninety degrees, and forearm and wrist in neutral positions. The test is performed three times, and the results averaged to give the final result. 9 Of five possible settings, the second setting was used for all subjects, and results recorded as kilograms of force. 
Results
Thirty five patients (26 male) aged 24-84 years (mean (SD) 53.2 (15.2)) participated. Causes of chronic renal failure were glomerulonephritis (9/35, 26%), unknown cause (9/35, 26%), reflux nephropathy (5/35, 14%), polycystic kidney disease, diabetes mellitus, and IgA nephropathy each 2/35, (6%), Alport's disease, pre-eclampsia, Goodpasture's syndrome, lithium toxicity, renovascular disease, and primary amyloidosis each 1/35 (3%). Ten patients had undergone a previous failed renal transplantation, with three patients having received three transplants. The average graft survival was 4.4 years (range from one never functioning graft to 28 years). The duration of haemodialysis (excluding periods of functioning renal allografts) ranged from one month to 25 years (mean 6.2 (7.8) years, median 2 years). All patients were dialysed three times a week for four hours, using bicarbonate buVer, and predominantly polysulphone membranes (one patient used a cellulose membrane and one used a triacetate membrane). The fistula was in the non-dominant arm in 20/35 (57%) subjects. Seven patients had undergone parathyroidectomy, nine had previous surgically corrected carpal tunnel syndrome, 17 had symptoms of peripheral arthritis, and 13 had symptoms of axial arthropathy. Table 1 shows the mean, median, and range of scores obtained for HAQ, VAS-P, VAS-F, JAMAR-D, JAMAR-ND, Sollerman-D, and Sollerman-ND. The median Sollerman score was 77, with 19/35 (54%) patients receiving haemodialysis having a score below the lower normal value of 78-80. The frequency distributions for Sollerman scores (dominant and non-dominant) were skewed (marked clustering between 73 and 80), hence the scores were log transformed for statistical analysis. Although the frequency distributions for HAQ, VAS-P, and VAS-F were also skewed, log transformation was not performed because a large proportion of subjects had scores of zero.
There was no significant diVerence between the Sollerman scores for the dominant and non-dominant hands and therefore other comparisons were made with the Sollerman score for the dominant hand only (table 2) . There was no correlation between Sollerman scores and age. The Sollerman score correlated most strongly with the HAQ score but also correlated with the duration of dialysis, VAS-P, VAS-F, and JAMAR-D.
Discussion
Of the total daily synthesis of 2 microglobulin (150-200 mg), 10 only a small fraction is removed by haemodialysis. With haemodialysis, the accumulation and deposition of this polypeptide in musculoskeletal structures leads to dialysis related amyloidosis. Age above 40 years at the start of dialysis, 11 duration of haemodialysis, 12 and the use of cuprophane membranes are identified risk factors.
The Jebsen test is a norm referenced instrument which provides a quantitative measure of seven aspects of unilateral hand function, and assesses the speed, rather than the quality of the performance. 7 The time taken to perform the Jebsen test is strongly correlated with scores obtained using the Sollerman test. 8 The Sollerman test is a more sensitive measure of functional performance than the Jebsen test, as indicated by the patients' subjective estimation of hand function. 8 The two tests, however, provide distinct information, and the test used depends on the criterion of hand function to be assessed.
The incidence of impaired hand function in our group undergoing haemodialysis, as indicated by the Sollerman test, was substantial, with 19/35 (54%) patients scoring below the lower normal value. The negative correlation of the log Sollerman-D score with the HAQ, VAS-P, and VAS-F scores (table 2) indicates that measurement of hand function by the Sollerman test accurately reflects the patients' subjective assessment of pain and functional limitation. By extrapolation, reducing pain and improving function should lower the HAQ, VAS-P, and VAS-F scores, and simultaneously improve the Sollerman scores. This measure, therefore, could be used in serial measurements in following up patients with dialysis related amyloidosis, and documenting objectively the eVect of interventional strategies (for example, hand treatment programmes). Once functional limitation from 2 microglobulin deposition has developed, the limitation as indicated by the Sollerman test seems to be bilateral-there was no significant diVerence in the Sollerman scores between the dominant and non-dominant hands. Grip strength as indicated by the JAMAR test correlated well with the Sollerman-D score (r s =0.57, p<0.05) and it is not surprising that hand functional impairment should occur in parallel with a reduction in grip strength.
Reduction in the Sollerman-D score with increasing duration of haemodialysis (table 2) is biologically plausible, and duration of haemodialysis is an identified risk factor for the development of dialysis related amyloidosis. 12 The Sollerman score was independent of age (p=0.35, r s =0.16) within the age range studied (24-84 years), and this test therefore appears suitable for a wide age group.
The wide range in age and duration of haemodialysis of our study group are the major limitations of this study. Furthermore, although dialysis related amyloidosis was the presumed cause of hand dysfunction, patients with other comorbidities aVecting hand function were excluded. The use of the Sollerman test in other conditions in which hand dysfunction is common (for example, rheumatoid arthritis) has not been evaluated, and application of this test to such conditions may prove similarly beneficial.
The functional consequences of 2 microglobulin deposition in the hand can be debilitating. We have, for the first time, shown that the Sollerman test reliably measures such alteration in hand function in activities of daily living. This test, unlike the HAQ, VAS-P, and VAS-F, requires active patient participation, while maintaining an objective, validated scoring system. We propose its use for the detection of dialysis related amyloidosis, and thereby target those at risk for the use of the more biocompatible membranes. Individualised hand treatment programmes, targeting areas of deficiency identified by the Sollerman test should be implemented, and the use of this test in serial measurements is encouraged.
